PMID: 74 van den BergEHFlores-GuerreroJLGruppenEGde BorstMHWolak-DinsmoreJConnellyMAet al
Available from: Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al
Glucagon-Like Peptide -1 or GLP-1 drugs, originally developed for treatment of diabetes, have recently grabbed the headlines as users have reported immediate and often effortless weight loss results
A network meta-analyses put tirzepatide clearly ahead on weight loss, which is the expected outcome for a dual GLP-1/GIP agonist versus a single GLP-1 agonist
McCann, M
As a compound designed to interact with multiple hormonal pathways involved in glucose regulation, appetite signaling, and energy balance, it represents a new generation of advanced injectable agents being explored in clinical settings